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Deﬁciency of periostin protects mice against
methionine-choline-deﬁcient diet-induced
non-alcoholic steatohepatitis
phenotypes of steatosis, inﬂammation and ﬁbrosis. The protein
and mRNA levels of liver periostin in mice fed the MCD diet for
8 weeks were also signiﬁcantly upregulated (data not shown).
These data suggest that periostin may be involved in the
development of MCD diet-induced NASH.
To determine whether periostin deﬁciency abrogates the
progression of NASH, we used a periostin-deﬁcient mouse model.
Heterozygous B6;129-Postntm1Jmol/J (Postn+/) mice were pur-
chased from the Jackson Laboratory (Bar Harbor, Maine, USA).
Periostin-deﬁcient and periostin wild type mice were generated
from crossing Postn+/ with Postn+/ mice. After feeding the
MCD diet for 4 weeks, periostin-deﬁcient mice exhibited signiﬁ-
cantly less TGs in their livers compared to the wild type group
(Fig. 1D). The serum level of alanine aminotransferase was mark-
edly decreased in Postn/ mice compared to wild type mice
(Fig. 1E), indicating that the MCD diet produced a more severe
liver injury in wild type mice than in Postn/ mice. Moreover,
MCD diet feeding resulted in an increased collagen deposition
in wild type mice, as shown by Sirius red staining; however, col-
lagen deposition was signiﬁcantly lower in Postn/ mice than in
wild type mice after being on the MCD diet (Fig. 1F and G), sug-
gesting that Postn/ mice exhibited signiﬁcantly less histological
ﬁbrosis compared to the wild type group. We also found that
mRNA levels of the inﬂammatory and ﬁbrotic factors IL-6, TGF-b1,
and a-SMA were markedly increased in livers of MCD diet-fed
wild type mice compared to the chow diet-fed wild type controls;
however, the mRNA levels of IL-6, TGF-b1, and a-SMAwere signif-
icantly lower in the liver tissue of Postn/ mice than in wild type
mice after being on the MCD diet for 4 weeks (Fig. 1H). Therefore,
these data suggest that a deﬁciency in periostin abrogates the
development of MCD diet-induced NASH in mice.
In conclusion, our work demonstrates that periostin is highly
expressed in MCD diet-induced NASH and that periostin knock-
out mice show a markedly lower degree of steatosis, inﬂamma-
tion and ﬁbrosis compared with wild type mice after being fed
the MCD diet. As previously mentioned, hepatic periostin levels
are signiﬁcantly upregulated in monogenic-induced obese mice
and HFD-fed mice, as well as in patients with fatty liver disease
[8]. Therefore, these data demonstrate that periostin is a potential
diagnostic marker and therapeutic target for hepatosteatosis,
NASH and even other liver diseases.
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Non-alcoholic fatty liver disease (NAFLD), themost common cause
of chronic liver diseaseworldwide, encompasses a spectrumof dis-
eases ranging from simple steatosis to non-alcoholic steatohepati-
tis (NASH) [1,2]. Periostin (encoded by POSTN), a matricellular
protein, plays an important role in various inﬂammatorydisorders,
such as airway inﬂammation, skin inﬂammation, atherosclerosis
and ﬁbrosis [3,4], and actively contributes to tumour metastasis
[5–7]. However, until the recent publication by Lu et al. [8], there
wasnoknown linkbetweenperiostin andNAFLD. Lu et al. [8] found
that hepatic periostin expression is dramatically increased in high-
fat diet (HFD)-fed mice, ob/ob mice and db/db mice, as well as in
NAFLD patients. Lu et al. [8] further demonstrated that periostin
is a crucial contributing factor in aberrant hepatic triglyceride
(TG) accumulation and in the pathogenesis of obesity-induced
hepatosteatosis. However, the role of periostin in the pathogenesis
of NASH remains unknown [9]. As an aggressive form of fatty liver
disease, NASH is characterized by histopathological features, such
as steatosis, inﬂammation and ﬁbrosis, and is often accompanied
by the metabolic syndrome, such as diabetes, insulin resistance
and obesity. Moreover, some individuals with NASH eventually
advance to liver cirrhosis and/or hepatocellular carcinoma,
whereas hepatic steatosis usually has no serious clinical
consequences [2,9]. Because genetically induced rodent obesity
or HFD-induced hepatic steatosis does not progress to steatohepa-
titis, we now present data to determine the role of periostin
in the development of methionine-choline-deﬁcient (MCD) diet-
induced NASH in mice.
To reveal the role of periostin in the development of NASH, we
fed two groups of C57BL/6J mice with either regular chow or the
MCD diet for 4 weeks. MCD diet-fed mice developed hepatic
steatosis whereas chow-fed mice did not develop steatosis. The
MCD diet also resulted in inﬂammation and ﬁbrosis in mouse
liver tissue (data not shown). We found that periostin was
markedly upregulated and mainly distributed around steatotic
hepatocytes in the MCD diet-fed mice by immunohistochemical
staining (Fig. 1A). Western blotting and qRT-PCR analyses further
demonstrated that the protein and mRNA levels of liver periostin
were dramatically increased in MCD diet-fed mice compared
with control mice (Fig. 1B and C). Moreover, we found that mice
fed the MCD diet for 8 weeks, also developed NASH and showedJournal of Hepatology 2015 vol. 62 j 492–501 495
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Fig. 1. Periostin contributes to the development of MCD diet-induced NASH in mice. The protein and mRNA levels of periostin in the livers of mice fed with either chow
(n = 5) or MCD (n = 4) diets for 4 weeks were determined by immunohistochemical staining (A), Western blotting (B) or qRT-PCR (C) analyses. (D) TG contents were
detected in livers of wild type and Postn/ mice, fed with chow or MCD diet for 4 weeks (n = 4 in each group). (E) Serum alanine aminotransferase (ALT) levels were
determined in wild type and Postn/ mice, fed with chow or MCD diet for 4 weeks (n = 4 in each group). (F) Collagen depositions in the livers of wild type and Postn/
mice, fed with chow or MCD diet for 4 weeks were detected by Sirius red staining. (G) Collagen deposition of the Sirius red stained positive areas in (F) were quantiﬁed by
Image Proplus 6.0 (n = 4 in each group). (H) The mRNA levels of IL-6, TGF-b1, and a-SMA in the livers of wild type and Postn/ mice, fed with chow or MCD diet for 4 weeks,
were determined by qRT-PCR analysis. (n = 4 in each group. ⁄p <0.05; ⁄⁄p <0.01; n.s., not signiﬁcant).
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TERT promoter mutation during development of hepatoblastoma
to hepatocellular carcinoma
To the Editor:
We read with great interest the article by Eichenmüller et al. [1],
who used whole-exome sequencing to describe the genomic
landscape of hepatoblastoma (HB) cells and their progenies with
hepatocellular carcinoma (HCC)-like features. They concluded
that mutation of CTNNB1 and activation of the NFE2L2-KEAP1
pathway are important features in HB-development and further
deﬁne loss of genomic stability and TERT promoter mutations
as prominent characteristics of aggressive HB with HCC features.
Although we appreciate these impressive ﬁndings, there are
some important considerations that need to be stressed.
First, HB and HCC share a common CTNNB1 mutation, which
leads to activation ofWnt signalling and the genesis of liver cancer
in both adults and children. The oncogene TERT has been shown to
regulate CTNNB1 expression, while conversely b-catenin can bind
to the TERT promoter to positively inﬂuence TERT expression [2,3].
TERT promoter mutations are commonly involved in the last step
of malignant transformation in association with CTNNB1 muta-
tions in HCC [4]. Eichenmüller et al. showed that the expression
of TERT was upregulated in both HB and transitional liver cell
tumours (TLCT). However, TERT promoter mutations were identi-
ﬁed in two thirds of TLCTs analysed but not in any instances of HB.
They concluded that the TERT promoter mutation is a selective
phenomenon for advanced HB with HCC-like features. However,
only three patients were included as TLCT controls, and the
cause(s) of their disease were not speciﬁed. Moreover, one of
the TLCT controls did not possess mutations of the TERT promoter.
This limited incidence of TLCT may inﬂuence the conclusion that
TLCT is a genetically derailed progeny of HB. Analysis of TERT pro-
moter mutations in paediatric HCC may assist in making such a
conclusion more convincing.
Second, it has been recently reported that the TERT promoter
mutation is an early event in liver carcinogenesis of cirrhosis,
based upon analysis of the sequence of lesions from cirrhosis to
low-grade dysplastic nodules (LGDN), high-grade dysplastic nod-
ules (HGDN), early HCC (eHCC) and small and progressed HCC.
TERT promoter mutations occurred in a small proportion of dys-
plastic nodules (6% of LGDN and 19% of HGDN), and the prevalence
increased with the degree of dysplasia. The prevalence of TERT
promoter mutations was dramatically increased in eHCC (61%),
suggesting a molecular shift had occurred following development
of eHCC [5]. These ﬁndings suggest that TERT promoter mutations
might be an important mechanism to drive malignant liver cells
towards a more aggressive eHCC-like phenotype. TERT promoter
mutations may therefore be a selective phenomenon of advanced
HB with eHCC-like features. Furthermore, TERT promoter
mutationswere signiﬁcantly associatedwith histological (pseudo-
glandular formation, cytological atypias, and unpaired arteries)
and immunohistochemical (positive staining for GPC3 and
HSP70) features of malignancy [5].
Therefore, Eichenmüller et al. should further evaluate their
data by examining paediatric HCC patient samples for the afore-
mentioned histological and immunohistochemical features.
Alternatively, a larger case-control study that incorporates the
above-mentioned points is required.
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